| Item Type | Name |
|
Concept
|
Dose-Response Relationship, Drug
|
|
Academic Article
|
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
|
|
Academic Article
|
Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group.
|
|
Academic Article
|
Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study.
|
|
Academic Article
|
Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia.
|
|
Academic Article
|
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia.
|
|
Academic Article
|
Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial.
|
|
Academic Article
|
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
|
|
Academic Article
|
Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin.
|
|
Academic Article
|
Reducing residual risk for patients on statin therapy: the potential role of combination therapy.
|
|
Academic Article
|
Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.
|
|
Academic Article
|
Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
|
|
Academic Article
|
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).
|
|
Academic Article
|
Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
|
|
Academic Article
|
Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy.
|
|
Academic Article
|
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
|
|
Academic Article
|
Safety of aggressive lipid management.
|
|
Academic Article
|
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
|
|
Academic Article
|
High-dose statin therapy: benefits and safety in aggressive lipid lowering.
|
|
Academic Article
|
One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
|
|
Academic Article
|
Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet.
|
|
Academic Article
|
Peripheral artery disease, biomarkers, and darapladib.
|
|
Academic Article
|
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.
|
|
Academic Article
|
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
|
|
Academic Article
|
Apolipoprotein A-I therapy promise, challenges, and disappointment.
|
|
Academic Article
|
Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial.
|
|
Academic Article
|
Risk for myopathy with statin therapy in high-risk patients.
|
|
Academic Article
|
Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups.
|
|
Academic Article
|
Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.
|
|
Academic Article
|
Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial.
|
|
Academic Article
|
Perceived patient threat and neuroleptic dosage.
|
|
Academic Article
|
Marine oil capsule therapy for the treatment of hyperlipidemia.
|
|
Academic Article
|
Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
|
|
Academic Article
|
A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease.
|
|
Academic Article
|
Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.
|
|
Academic Article
|
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST).
|
|
Academic Article
|
Overcoming toxicity and side-effects of lipid-lowering therapies.
|
|
Academic Article
|
A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.
|
|
Academic Article
|
Intensive statin therapy in India: Demonstrating efficacy and safety.
|
|
Academic Article
|
Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.
|
|
Academic Article
|
Effects of ipsapirone in healthy subjects: a dose-response study.
|
|
Academic Article
|
Long-term safety of risperidone.
|
|
Academic Article
|
What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?
|
|
Academic Article
|
Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials.
|